How a digital side hustle expanded into stores in London and New York
This so-called discovery studio is primarily a retail space; the walls lined with cases of watches from Furlan Marri to Zodiac. But it also doubles as a media office for T+T's editorial website, while providing an informal clubhouse for watch lovers. On Watch 's visit, three punters are lounging on a banquette sipping cold bottles of Peroni. 'I wanted a place where people felt like they could hang out and have a beer,' McUtchen says of his multipurpose boutique. 'But also one that was still clearly transactional and not too confusing.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
6 days ago
- News.com.au
Top 10 at 11: ASX falls as tariffs bring headwinds
Morning, and welcome to Stockhead's Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks off in earnest. In brief, this is what the market has been up to this morning. In the cold hard light of morning News the EU had managed to secure a trade deal with the US was enough to soothe markets yesterday, lifting a solid 0.36% on broad market gains. This morning, the truth of the matter is sinking in. While avoiding the 30-50% tariffs on EU goods Trump had been threatening was definitely a win for the global economy, the overall increase in tariffs is still a net loss. In 2022, the trade weighted average global tariff was about 4%. Obviously, there are a huge range of trade agreements and regional or sector specific tariffs are common, but something like two thirds of all global trade was entirely tariff free. The new reality is looking closer to a 15% tariff on most goods, a 3-fold increase, and that's going to have long-term and far-reaching effects on the global economy. The ASX fell as much as 0.33% in the first hour this morning, with 8 of 11 sectors retreating. The financials sector is leading losses, down 0.75%, while energy mounts a resistance, climbing 0.37% on a 2% lift in oil prices overnight. WINNERS Code Name Last % Change Volume Market Cap RAN Range International 0.003 50% 37086 $1,878,581 BEO Beonic Ltd 0.295 37% 64555 $15,235,117 HLX Helix Resources 0.002 33% 2000000 $5,046,291 OSX Osteopore Limited 0.015 25% 5083213 $2,485,674 ALR Altairminerals 0.005 25% 12936351 $17,186,977 CAV Carnavale Resources 0.005 25% 11000 $16,360,874 PKO Peako Limited 0.0025 25% 33333 $2,975,484 ADG Adelong Gold Limited 0.006 20% 268333 $11,243,383 DRE Dreadnought Resources 0.012 20% 3152528 $50,795,000 FBR FBR Ltd 0.006 20% 2000566 $28,447,261 In the news... LiDAR-based logistics company Beonic (ASX:BEO) has secured a contract to deploy its passenger flow management technology across seven major international airports in north Africa. BEO reckons the contract is worth about $10.6m over its 2.5-year term, with an option to extend for another 3 years. The company is already operating in the London Heathrow, JFK Terminal 4, Narita and Abu Dhabi airport hubs. Back in July 2024, regenerative medicine company Osteopore (ASX:OSX) inked an exclusive agreement with a subsidiary of Zimmer Biomet Holdings to distribute OSX craniofacial products in Europe, the Middle East and Africa, and the Asia Pacific. In the first 12 month of the partnership implant sales in Europe, Australia and Hong Kong tripled compared to the year before. Management says it's clear evidence of the market's appetite for OSX products and demonstrates the resilience of Osteopore's manufacturing capability. LAGGARDS Code Name Last % Change Volume Market Cap ANR Anatara Ls Ltd 0.006 -33% 3175653 $1,920,454 DTM Dart Mining NL 0.003 -25% 8365431 $4,792,222 MRQ Mrg Metals Limited 0.003 -25% 125000 $10,906,075 SFG Seafarms Group Ltd 0.0015 -25% 1 $9,673,198 RFT Rectifier Technolog 0.004 -20% 2500 $6,909,920 KZR Kalamazoo Resources 0.09 -18% 2520457 $24,133,287 TMX Terrain Minerals 0.0025 -17% 3666666 $7,595,443 GTR Gti Energy Ltd 0.003 -14% 496738 $13,029,292 CHR Charger Metals 0.052 -13% 149718 $4,645,215 NIM Nimyresourceslimited 0.06 -12% 787417 $16,352,694
Mercury
7 days ago
- Mercury
Prescient advances cancer drug to unlock value
Prescient at critical stage of development with phase 2a trial underway for PTX-100 PTX-100 granted orphan drug and fast track designations by the US FDA, unlocking benefits Focus on advancing PTX-100 to potential registrational phase 2b trial to open commercial opportunities Special Report: Prescient Therapeutics has entered a critical stage where clinical data, regulatory support, and commercial potential begin to converge in a defining moment for a biotech company aiming to bring a new therapy to market. Prescient Therapeutics (ASX:PTX) is in phase 2a trial for its lead compound PTX-100 in patients with rare blood cancer relapsed/refractory Cutaneous T-Cell Lymphoma (r/r CTCL) with the potential for its phase 2b arm to be registrational. PTX-100 is a first-in-class compound with the ability to block an important cancer growth enzyme geranylgeranyl transferase-1 (GGT-1). It is believed to be the only GGT-1 inhibitor in the world in clinical development. The US Food and Drug Administration (FDA) has granted PTX-100 orphan drug designation (ODD) for all T-cell lymphomas and fast-track designation for treatment of adults with relapsed or refractory mycosis fungoides, the most common subtype of CTCL. Fast Track designation provides an expedited pathway to approval, with orphan drug designation offering market exclusivity for a period of seven years in the US. 'The aim is to improve the quality of life for people suffering from this terrible form of cancer and getting them the therapy they need as fast as possible,' CEO James McDonnell said. 'It's also an incentive for larger pharmaceuticals who are looking to add to their portfolio as the drug progresses through clinical development.' Potential regulatory trial for PTX-100 McDonnell is focused on getting PTX-100 through the phase 2a trial with the potential to make the second phase 2b arm a registration study. 'Fast Track designation opens a dialogue with the FDA for companies to provide ongoing trial updates, instead of a lengthy review at the end, to expedite therapies to patients who desperately need them,' he said. 'All we need to do is replicate the Phase 1b results, if the FDA agrees, they could potentially authorise Phase 2b as a registration study.' In the phase 1b trial PTX-100 delivered a 45% overall response rate and 64% clinical benefit in T-cell lymphoma, with just 4% serious side effects – well below the 30% benchmark. 'The first step now is to progress Phase 2a where we can define a dose which will also have some efficacy and safety data,' McDonnell said 'The registrational study means we are closer to approval and the momentum for PTX-100 really starts to accelerate and excitement grows on the commercial front.' Watch: James McDonnell discusses the first US site for the Phase 2a trial of PTX-100. Eyes on the commercialisation prize With over 27,000 new TCL cases every year, in eight major centres, PTX is targeting a market worth ~US$1.8 billion. Commercialisation of PTX-100 will become a key focus for Prescient if it advances to a registrational study, with all options on the table – including partnership, licensing, or taking the drug to market independently. 'We are confident in how PTX-100 could change the lives of thousands, we need the data now to back that confidence and provide the market a clear indication of the value the therapy can provide,' he said. 'PTX-100 is a first-in-class therapy with a unique mechanism of action which has shown very good results in the Phase 1b study. 'These results have exceeded our benchmarks and compare well to the available therapies on efficacy, duration and a safety perspective.' McDonnell said that Dimerix (ASX:DXB) was a great example of what a potential commercial pathway could look like for Prescient if Phase 2b became a registrational trial. Dimerix is advancing its lead candidate DMX-200 through the ACTION3 phase 3 trial for the rare kidney disease FSGS and has secured four regional licensing agreements to drive commercialisation. 'They were able to take orphan drug designated therapy DMX-200, which is currently in a phase 3 registration study, into significant licensing agreements worth approximately $1.4 billion,' he said. 'Dimerix have highlighted how these milestones, FDA designation and registrational study, can open commercialisation opportunities and drive value creation.' McDonnell said in biotech it often comes down to two questions with the first being: can you get a product to market? The second is: what kind of market is waiting at the end? Phase 2 trials usually provide clearer insights into a drug's potential, with data readouts serving as critical indicators that can drive value inflection points. Source: Prescient Therapeutics A series of upcoming catalyst Investors have plenty to watch out for in H2 CY25, with Prescient advancing its phase 2a study. 'We are excited for the release, once we reach 20 patients, of the initial data from the dose optimisation committee review, which will be a key event in determining the next steps for development of PTX-100,' McDonnell said. A share purchase plan aimed at raising $7 million to support Prescient's clinical program closed on July 25. 'There are several milestones we are looking to hit in the coming months and if we can potentially get that Phase 2b into a registration study we can start to shift our focus toward commercialisation opportunities,' McDonnell said. This article was developed in collaboration with Prescient Therapeutics, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Prescient focuses on advancing lead cancer drug toward pivotal trial
AU Financial Review
24-07-2025
- AU Financial Review
How a digital side hustle expanded into stores in London and New York
Time+Tide's London premises is tucked inside the first floor of a building around the corner from Oxford Street's bustle. Inside the 170-square-metre space, T+T founder Andrew McUtchen is chatting to Matteo Violet-Vianello, the man behind the new microbrand Anoma, while a shop assistant discusses the finer points of a Nivada Grenchen chronograph with a customer. This so-called discovery studio is primarily a retail space; the walls lined with cases of watches from Furlan Marri to Zodiac. But it also doubles as a media office for T+T's editorial website, while providing an informal clubhouse for watch lovers. On Watch 's visit, three punters are lounging on a banquette sipping cold bottles of Peroni. 'I wanted a place where people felt like they could hang out and have a beer,' McUtchen says of his multipurpose boutique. 'But also one that was still clearly transactional and not too confusing.'
